A client reports taking ergotamine for treatment of migraine headaches. The nurse recognizes that this drug has which warning associated with it?

A. Avoid use with CYP3A4 inhibitors: Ergotamine is extensively metabolized by the cytochrome P450 3A4 (CYP3A4) enzyme. Concomitant use with strong CYP3A4 inhibitors (such as certain antifungals, macrolide antibiotics, or protease inhibitors) can dramatically increase plasma levels, leading to severe vasospasm, ischemia, or ergot toxicity. This drug–drug interaction is a critical safety warning for patients taking ergotamine. B. May cause respiratory depression when taken with benzodiazepines: Respiratory depression is primarily a concern with central nervous system depressants such as opioids or high-dose benzodiazepines. Ergotamine does not have significant CNS depressant effects and is not known to cause additive respiratory depression with benzodiazepines. C. May cause liver damage when taken with acetaminophen: Ergotamine hepatotoxicity is not commonly associated with acetaminophen co-administration. Liver injury from ergotamine is rare and typically linked to chronic overuse or overdose, not interactions with acetaminophen. D. Avoid use with NSAIDs: Nonsteroidal anti-inflammatory drugs do not significantly affect the metabolism or toxicity of ergotamine. There is no major contraindication for concurrent use solely based on NSAID administration, although overall vascular and gastrointestinal considerations may still apply.